Is pemetinib/pemetinib a new choice for domestic hospitals?

Pemigatinib/Pemigatinib (Pemigatinib) is a cutting-edge targeted therapy drug designed to fight certain malignant cancers, such as refractory cholangiocarcinoma and myeloid/lymphoid tumors with FGFR1 rearrangements. Its advent opens a window of hope for patients with advanced cholangiocarcinoma who are in treatment dilemma. However, before deciding to use it, it is essential to have an in-depth understanding of its indications, mechanism of action and potential risks, which are related to the safety and effectiveness of the treatment.

Since starting from April 6, 2022, pemetinib has been officially approved by the National Medical Products Administration of my country and has begun to circulate in the domestic market. This means that a large number of patients can now find this valuable treatment resource in the country's first-class hospitals. In addition, patients have more options for purchasing drugs, such as purchasing through qualified drug dealers or legal online drug platforms.

The use of any drug must be under the guidance of a doctor, and pemetinib is no exception. At the same time, since the price and insurance coverage of drugs vary by region and hospital, it is best for patients to conduct detailed consultation with the relevant medical institutions or insurance companies to obtain the most accurate and up-to-date information before deciding to purchase.

Although pemetinib is currently on the market in China, unfortunately it has not yet been included in my country's medical insurance coverage, which makes its price relatively high. The price of each box may reach around RMB 50,000. In overseas markets, the price of pemetinib is also high, and the price of each box may be as high as RMB 70,000 (the actual price may change due to exchange rate fluctuations).